Drugs for Neglected Diseases initiative - DNDi
Graeme Bilbe is a seasoned professional in the field of biomedical research with extensive experience spanning over three decades. Currently serving as Senior Advisor and Chief Scientific Officer at the Drugs for Neglected Diseases initiative (DNDi) since June 2012, Bilbe previously held significant roles at Novartis Institutes for BioMedical Research, including Global Head of Neuroscience Discovery and Head of Psychiatric Research, from July 1996 to April 2012. Early career contributions were made at Ciba-Geigy as Head of Cell and Molecular Biology and at Zentrum fuer Molekular Biologie as a Postdoctoral Assistant. Graeme Bilbe holds a PhD in Biochemistry from Imperial College London and a BSc in Zoology/Biochemistry from the University of Nottingham.
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.